Theralink Technologies Inc (THER)

[BooDog]

European Medicines Agency

Litak -

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000504/human_med_000888.jsp&mid=WC0b01ac058001d124

https://www.drugs.com/uk/litak.html

Dacin

https://www.drugs.com/international/dacin.html

https://www.lipomed.com/index.php?page=382

https://www.lipomed.com/

Message in reply to:

(MKTW) OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico
38 minutes ago - DJNF
OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico
BATON ROUGE, LA--(Marketwired - August 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce written confirmation that the Company has been designated as the exclusive distributor of the product portfolio of Lipomed AG. Lipomed is a world leader for Reference Standards with specialization in the research, development and manufacturing of pharmaceuticals and products for the treatment of rare diseases from its state-of-the-art production facilities in Arlesheim, Switzerland.

OncBioMune intends to first focus on Litak (cladribine) and Dacin (dacarbazine), the two drugs that the Company believes can achieve immediate market penetration in Mexico. Litak is an antineoplastic agent primarily used for the treatment of hairy cell leukemia, with other uses for different types of blood cancers and lymphoma. Dacin is a chemotherapeutic drug currently used to treat various forms of cancer, including metastatic malignant melanoma and Hodgkin's disease.

"The partnership with Lipomed represents a milestone moment for us as part of our mission to introduce promising oncology products in Mexico," said Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We are working closely with Lipomed on finalizing the details of the agreement and look forward to providing guidance on expected time to launch and sales in the near future."